The CA‐125 blood test has been the most utilized clinical tool for screening, detecting, and managing ovarian cancer for over four decades with approximately 92% of advanced‐stage serous ovarian cancers exhibiting elevated levels.3 The gene discussed is MUC16; the disease is ovarian serous adenocarcinoma.